Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.73) per share for the quarter.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.13. The business had revenue of $127.39 million for the quarter, compared to the consensus estimate of $119.38 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.16) earnings per share. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Ultragenyx Pharmaceutical Trading Up 0.6 %
Shares of NASDAQ RARE traded up $0.25 during mid-day trading on Friday, reaching $44.10. The company had a trading volume of 42,808 shares, compared to its average volume of 749,782. The business’s 50-day moving average is $47.89 and its 200-day moving average is $43.75. The stock has a market cap of $3.63 billion, a price-to-earnings ratio of -5.29 and a beta of 0.65. Ultragenyx Pharmaceutical has a 52 week low of $31.52 and a 52 week high of $54.98.
Insider Buying and Selling at Ultragenyx Pharmaceutical
Wall Street Analysts Forecast Growth
Several research firms have commented on RARE. Royal Bank of Canada began coverage on shares of Ultragenyx Pharmaceutical in a research report on Monday. They set an “outperform” rating and a $77.00 price target for the company. TD Cowen increased their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the company a “buy” rating in a research report on Wednesday. Wedbush reissued a “neutral” rating and set a $48.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, April 16th. Canaccord Genuity Group increased their price target on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. Finally, Robert W. Baird increased their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $88.08.
Check Out Our Latest Stock Analysis on Ultragenyx Pharmaceutical
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Further Reading
- Five stocks we like better than Ultragenyx Pharmaceutical
- What Investors Need to Know to Beat the Market
- 3 Stocks Leading the U.S. Agriculture Comeback
- Why is the Ex-Dividend Date Significant to Investors?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How Can Investors Benefit From After-Hours Trading
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.